Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Autoimmune
Cancer
Cardiovascular
COVID-19
Health Topics
Infectious
Mesothelioma
Genialis partners with OncXerna to improve targeted therapy
By
LabPulse.com staff writers
Genialis' ResponderID will use OncXerna's XernaTME (tumor microenvironment) panel to incorporate the pancancer tumor microenvironment classifier to investigate potentially hundreds of new use cases for personalized therapeutic selection.
April 5, 2022
Page 1 of 1
